Plain-English translation of NCT05744479 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether , a medication commonly used to treat diabetes, can help reduce weight gain caused by antipsychotic medications. Adults with intellectual or developmental disabilities who have gained weight while taking antipsychotics are needed for this study. The research will help doctors find a safe, practical way to support healthier weight in this group of people.
People with intellectual and developmental disabilities face serious health challenges from weight gain linked to antipsychotic medications, but they are rarely included in research studies. This trial will be the first to test this medication in this population, creating evidence that doctors can actually use to help their patients.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive either the medication or an identical-looking placebo pill for 24 weeks. You will take your assigned treatment by mouth, starting at a low dose that gradually increases to the maximum dose. You will have regular visits to monitor your weight, health, and how well the treatment is working.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Canada